UNSPSC 51313003: Azelastine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C22H24ClN3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0L591QR10I, chemically known as 1(2h)-phthalazinone, 4-((4-chlorophenyl)methyl)-2-(hexahydro-1-methyl-1h-azepin-4-yl)-, monohydrochloride but more generally known as azelastine hydrochloride, which bears US NIH Compound Identifier 54360.

UNSPSC 51313003 Azelastine hydrochloride is a Commodity code that in practice receives limited direct solicitation under its specific designation; recent state and local opportunities tagged to this code primarily reflect broader pharmaceutical procurement activity rather than purchases of this particular antihistamine nasal spray formulation. The code sits within a taxonomy designed for pharmaceutical inventory management, but the actual work posted under it spans generic multi-source pharmaceutical distribution agreements, naloxone and drug-deactivation system procurement, and pharmacy benefit program strategy sourcing. State and local buyers using this code—including county health departments, state health and human services commissions, and cooperative purchasing alliances—are acquiring pharmaceuticals, OTC products, and related delivery systems through a mix of IFBs, RFPs, and RFIs that establish ongoing supply relationships rather than one-time purchases.

Recent activity clusters in the South and Upper Midwest. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug-deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023, under a two-year contract with one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, gathering vendor capacity information for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—an exploratory solicitation signaling future formal procurement but carrying no budget or timeline commitment at the information-gathering stage. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026, response deadline, requiring cGMP and DSCSA compliance, relationships with authorized wholesalers, and EDI capability, with evaluation weighted 75 percent on price competitiveness. The cooperative structure and multistate reach of MMCAP contracts suggest ongoing demand for vendors positioned to supply through established distribution channels across multiple jurisdictions.